The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Opinion
  • Yun Byung-se
  • Kim Won-soo
  • Ahn Ho-young
  • Kim Sang-woo
  • Yang Moo-jin
  • Yoo Yeon-chul
  • Peter S. Kim
  • Daniel Shin
  • Jeffrey D. Jones
  • Jang Daul
  • Song Kyung-jin
  • Park Jung-won
  • Cho Hee-kyoung
  • Park Chong-hoon
  • Kim Sung-woo
  • Donald Kirk
  • John Burton
  • Robert D. Atkinson
  • Mark Peterson
  • Eugene Lee
  • Rushan Ziatdinov
  • Lee Jong-eun
  • Chyung Eun-ju
  • Troy Stangarone
  • Jason Lim
  • Casey Lartigue, Jr.
  • Bernard Rowan
  • Steven L. Shields
  • Deauwand Myers
  • John J. Metzler
  • Andrew Hammond
  • Sandip Kumar Mishra
  • Lee Seong-hyon
  • Park Jin
  • Cho Byung-jae
Tue, August 9, 2022 | 17:20
Kim Sang-woo
Global efforts for vaccination
Posted : 2021-05-20 16:25
Updated : 2021-05-20 16:25
Print Preview
Font Size Up
Font Size Down
By Kim Sang-woo

As the COVID-19 pandemic enters its second year, highly concerning variants have been identified in many countries, with scientists fearing that some of these new strains may be resistant to the recently produced vaccines.

In February, U.N. Secretary General Antonio Guterres announced that 10 countries had administered 75 percent of the world's available COVID-19 vaccine supply. At that time, more than 130 countries, home to 2.5 billion people, had yet to receive a single dose of any vaccine, rendering their populations vulnerable to the new variants.

High-income countries hope to get close to herd immunity through vaccination in the coming months. But they will still be in danger of the variants evolving in non-vaccinated or inadequately vaccinated countries, which will then make their way across international borders.

Such mutations could pose a major health threat to all countries, as well as disrupt the inter-connected global supply chain, by damaging manufacturing and agriculture in regions still blighted by the virus.

A January study published by the International Chamber of Commerce claims that unequal access to vaccines could cost the global economy as much as $9.2 trillion, with around half of the total loss being in wealthy countries.

To overcome these challenges, the World Health Organization (WHO) set up COVAX, an initiative to coordinate vaccine research and license production in order to guarantee fair and equitable distribution worldwide. To date, however, this effort has fallen desperately short.

As the pandemic rages in the unvaccinated world, vaccine nationalism prevalent in wealthy democracies raises the risk of them losing the soft power race to China and Russia, which have shipped vaccines to over 50 countries, including most of Latin America.

The vaccine donations by Russia and China, in exchange for favorable foreign policy concessions, are strong indications that the vaccine "have-nots" are vulnerable to diplomatic coercion and enticement.

The Western countries, meanwhile, are focused on their own domestic vaccination programs ― although the United States has recently declared its intention to offer vaccine aid to hard hit countries, especially India ― amounting to a total of 60 million doses, in which 20 million will be provided for India.

Despite all the arguments over vaccines in Europe, the most important element has been missed. The shortage of vaccines is not primarily a procurement problem but a production one. And these difficulties arise from the problem of vaccine patents limiting supply. However, a solution is possible through a coordinated global effort.

In the first phase of the pandemic, the relationship between a nation's wealth and its effective response was indirect. While testing capacity has been a problem in many countries, the non-pharmaceutical methods that were key to flattening the curve of the epidemic ― social distancing, mask-wearing, quarantines and contact tracing -- were often used effectively in poor and middle-income countries. Non-pharmaceutical solutions are less effective in the pandemic's new phase, which requires the entire world to be vaccinated urgently.

Governments have poured large amounts of public money into producing COVID-19 vaccines. The U.S. government alone, under "Operation Warp Speed," invested $8 billion. The Moderna vaccine has been almost entirely funded by U.S. taxpayers, but it is being sold at a fully commercial price for private profit.

Even though other companies, like AstraZeneca, are charging much less per dose, they still retain their patent rights over supply. Companies' profit-motivated practices mean that the full potential of global production is simply not being realized.

South Africa and India have proposed a temporary suspension of coronavirus patents. Implementing this suspension globally will allow manufacturers all over the world to join in the global effort. The WHO has backed this demand and established the "COVID-19 Technology Access Pool" to share knowledge and resources equitably, enabling a rapid exit from the pandemic.

In a revealing turn of events, it was established in March that the U.S. government has patent license claims over the Moderna, Johnson & Johnson, Novavax, CureVac, and Pfizer/BioTech vaccines. So, private monopoly control has become less justifiable.

On May 5, the Biden administration announced support for India and South Africa's proposal to waive the intellectual property rules on the COVID-19 vaccines "until widespread vaccination is in place globally." "These extraordinary times and circumstances … call for extraordinary measures," said U.S. Trade Representative Katherine Tai, pledging that the U.S. would support the waiver for COVID-19 vaccines in discussions at the World Trade Organization (WTO).

Unfortunately, the EU, with Germany in the forefront, has decided to oppose the waiver, arguing that the lack of vaccines is not a problem of patents, but is rather an issue of the ability to manufacture vaccines while maintaining a standard of high-quality, and if the intellectual property rights are lifted, that will have a detrimental effect on global vaccine production.

Since the waiver at the WTO requires a consensus, it is possible that it will either never be implemented, because others continue to object, or negotiations over the actual wording will take so long that it will be irrelevant by the time it's finished.

However, one thing is clear ― neither the EU nor any other global power can defeat a pandemic by thinking in national terms. COVID-19 vaccines are now a central component of the national security of every country in the world ― all the more reason for democracies to demonstrate moral leadership. They need to adopt measures that understand the scale of the global crisis and the courage to do what it takes to overcome the threat. For whom does the bell toll? It tolls for all of us.


Kim Sang-woo (swkim54@hotmail.com) is a former lawmaker and currently chairman of the East Asia Cultural Project. He is also a member of the board of directors at the Kim Dae-jung Peace Foundation.


 
LG
  • [ANALYSIS] Why Beijing won't retaliate against Seoul for 'Chip 4'
  • Surging costs of living push people to take side jobs
  • Retailers wage war with fried chicken amid soaring inflation
  • Gov't to increase quota for migrant workers
  • Education minister resigns after just over a month in office
  • Ruling party's self-inflicted crisis
  • Foreign ministers of South Korea and China to meet to address thorny issues
  • Family succession at major conglomerates put on hold due to lackluster IPO market
  • Ethereum founder expects crypto payments to become prevalent soon
  • Yoon vows to go back to basics amid low approval ratings
  • Interactive News
  • With tough love,
  • 'Santa dogs' help rebuild burnt forests in Andong
  • 'Santa dogs' help rebuild burnt forests in Andong
  • A tale of natural wine
    • [INTERVIEW] Leandro Erlich's questioning of our perception of reality carries new meaning in pandemic [INTERVIEW] Leandro Erlich's questioning of our perception of reality carries new meaning in pandemic
    • Netflix's 'Narco-Saints' to be released Sept. 9 Netflix's 'Narco-Saints' to be released Sept. 9
    • BLACKPINK to start world tour in October BLACKPINK to start world tour in October
    • [INTERVIEW] Im Si-wan found own narrative for villain role in 'Emergency Declaration' [INTERVIEW] Im Si-wan found own narrative for villain role in 'Emergency Declaration'
    • 'Free Chol Soo Lee': how young Korean immigrant's case led to pan-Asian American resistance movement 'Free Chol Soo Lee': how young Korean immigrant's case led to pan-Asian American resistance movement
    DARKROOM
    • Ice is melting, land is burning

      Ice is melting, land is burning

    • Tottenham 6-3 Team K League

      Tottenham 6-3 Team K League

    • Afghanistan earthquake killed more than 1,000

      Afghanistan earthquake killed more than 1,000

    • Divided America reacts to overturn of Roe vs. Wade

      Divided America reacts to overturn of Roe vs. Wade

    • Namaste: Yogis to celebrate International Yoga Day

      Namaste: Yogis to celebrate International Yoga Day

    The Korea Times
    CEO & Publisher : Oh Young-jin
    Digital News Email : webmaster@koreatimes.co.kr
    Tel : 02-724-2114
    Online newspaper registration No : 서울,아52844
    Date of registration : 2020.02.05
    Masthead : The Korea Times
    Copyright © koreatimes.co.kr. All rights reserved.
    • About Us
    • Introduction
    • History
    • Location
    • Media Kit
    • Contact Us
    • Products & Service
    • Subscribe
    • E-paper
    • Mobile Service
    • RSS Service
    • Content Sales
    • Policy
    • Privacy Statement
    • Terms of Service
    • 고충처리인
    • Youth Protection Policy
    • Code of Ethics
    • Copyright Policy
    • Family Site
    • Hankook Ilbo
    • Dongwha Group